Versant Capital Management, Inc Pacira Bio Sciences, Inc. Transaction History
Versant Capital Management, Inc
- $431 Million
- Q3 2024
A detailed history of Versant Capital Management, Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 846 shares of PCRX stock, worth $16,057. This represents 0.0% of its overall portfolio holdings.
Number of Shares
846
Previous 16
5187.5%
Holding current value
$16,057
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding PCRX
# of Institutions
263Shares Held
50.4MCall Options Held
429KPut Options Held
391K-
Black Rock Inc. New York, NY8.01MShares$152 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.3MShares$101 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.96MShares$94.2 Million0.18% of portfolio
-
State Street Corp Boston, MA2.01MShares$38.2 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.98MShares$37.6 Million0.05% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $870M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...